Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals™ OJEMDA„, new treatment for common pediatric brain tumor type
Day One drug for common childhood brain tumor approved by FDA
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA„ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023...
BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (œDay One or the œCompany), a clinical-stage biopharmaceutical company dedicated to developing and...
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (œDay One or the œCompany), a clinical-stage biopharmaceutical company dedicated to developing and...
BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (œDay One or the œCompany), a clinical-stage biopharmaceutical company dedicated to developing and...
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (œDay One or the œCompany), a clinical-stage biopharmaceutical company dedicated to developing and...
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress